Cargando…

Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells

Telomerase is required for the unlimited lifespan of cancer cells. The vast majority of pancreatic adenocarcinomas overexpress telomerase activity and blocking telomerase could limit their lifespan. GRN163L (Imetelstat) is a lipid-conjugated N3′→P5′ thio-phosphoramidate oligonucleotide that blocks t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burchett, Katrina M., Yan, Ying, Ouellette, Michel M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883701/ https://www.ncbi.nlm.nih.gov/pubmed/24409321 http://dx.doi.org/10.1371/journal.pone.0085155

Ejemplares similares

Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells
por: Burchett, Katrina M., et al.
Publicado: (2017)

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
por: Baerlocher, Gabriela M., et al.
Publicado: (2020)

Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton
por: MENDER, ILGEN, et al.
Publicado: (2013)

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma
por: Wu, Xuping, et al.
Publicado: (2017)

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models
por: Fischer-Mertens, Janina, et al.
Publicado: (2022)

Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner
por: Frink, Robin E., et al.
Publicado: (2016)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
por: Leibundgut, Elisabeth Oppliger, et al.
Publicado: (2020)

Telomerase Is Required for Zebrafish Lifespan
por: Henriques, Catarina M., et al.
Publicado: (2013)

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
por: Tefferi, A, et al.
Publicado: (2016)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
por: Olschok, Kathrin, et al.
Publicado: (2023)

Correction: Telomerase Is Required for Zebrafish Lifespan
por: Henriques, Catarina M., et al.
Publicado: (2017)

Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation
por: Yan, Ying, et al.
Publicado: (2014)

AAV-GRN partially corrects motor deficits and ALS/FTLD-related pathology in Tmem106b(−/−)Grn(−/−) mice
por: Feng, Tuancheng, et al.
Publicado: (2023)

Correction: Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation
por: Yan, Ying, et al.
Publicado: (2020)

Targeting telomerase-expressing cancer cells
por: Ouellette, Michel M, et al.
Publicado: (2011)

Novel GRN Mutations in Patients with Corticobasal Syndrome
por: Taghdiri, Foad, et al.
Publicado: (2016)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort
por: Sudre, Carole H., et al.
Publicado: (2017)

Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis
por: Boland, Sebastian, et al.
Publicado: (2022)

Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia
por: Panman, Jessica L, et al.
Publicado: (2021)

Improving GRN re‐construction by mining hidden regulatory signals
por: Shi, Ming, et al.
Publicado: (2017)

Glia in FTLD-GRN: from supporting cast to leading role
por: Pinarbasi, Emile S., et al.
Publicado: (2023)

Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome
por: Botha, Hugo, et al.
Publicado: (2017)

Limits to lifespan growth
por: Gonçalves, Marta, et al.
Publicado: (2023)

A limit on the mass of the electron neutrino: the case of $^{163}Ho$
por: Andersen, J U, et al.
Publicado: (1982)

Telomerase Reverse Transcriptase Increases Proliferation and Lifespan of Human NK Cells without Immortalization
por: Streltsova, Maria A., et al.
Publicado: (2021)

Elevated levels of extracellular vesicles in progranulin‐deficient mice and FTD‐GRN Patients
por: Arrant, Andrew E., et al.
Publicado: (2020)

Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease?
por: Caroppo, Paola, et al.
Publicado: (2015)

Immuno-hybrid algorithm: a novel hybrid approach for GRN reconstruction
por: Jereesh, A. S., et al.
Publicado: (2016)

Peripheral Innate Immune Activation Correlates With Disease Severity in GRN Haploinsufficiency
por: Ljubenkov, Peter A., et al.
Publicado: (2019)

IMPACT is a GCN2 inhibitor that limits lifespan in Caenorhabditis elegans
por: Ferraz, Rafael C., et al.
Publicado: (2016)

Transmembrane 163 (TMEM163) protein effluxes zinc
por: Sanchez, Vanessa B., et al.
Publicado: (2019)

Rac1 GTPase in pancreatic cancer
por: Yan, Ying, et al.
Publicado: (2015)

AZT as a telomerase inhibitor
por: Gomez, Daniel E., et al.
Publicado: (2012)

Targeting telomerase with radiolabeled inhibitors
por: Waghorn, Philip A., et al.
Publicado: (2017)

Oxoisoaporphine as Potent Telomerase Inhibitor
por: Wei, Zu-Zhuang, et al.
Publicado: (2016)

Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms
por: Bilsland, Alan E., et al.
Publicado: (2014)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_teig3p2l26s0b4ou40a16aec9k